Form 4: CEO Bradley Burnam Executes Family Stock Transfers

Turn Therapeutics CEO Bradley Burnam transferred 600,000 shares of common stock to family trusts via gift transactions.

Summary

• CEO Bradley Burnam transferred a total of 600,000 shares of Turn Therapeutics common stock on May 28, 2026.
• The shares were transferred from BEB Holdings, LLC, an entity controlled by the CEO, to two separate revocable trusts for his children.
• 300,000 shares were gifted to the Bradley E. Burnam 2026 Revocable Trust FBO Gabriella G. Burnam.
• 300,000 shares were gifted to the Bradley E. Burnam 2026 Revocable Trust FBO Luca M. Burnam.
• Following these transactions, the CEO maintains beneficial ownership of 15,116,260 shares through BEB Holdings, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a personal estate planning transaction with no impact on the company's financial position or operational strategy.

Positives

• The transaction reflects long-term estate planning rather than a divestment of interest in the company.
• The CEO maintains a significant controlling interest in the company post-transaction.

Negatives

• None identified; this is a routine internal transfer of ownership for estate planning purposes.

Risks

• Concentrated ownership remains with the CEO and his controlled entities, which may influence corporate governance decisions.

Future Outlook

No specific forward-looking guidance provided in this ownership disclosure.

Management Comments

• The reporting person disclaims beneficial ownership of the securities held by the GGB Trust and the LMB Trust.

Industry Context

StockSavvy.ai notes that insider gift filings are standard corporate governance disclosures and typically do not signal a change in management's confidence or operational outlook.

Comparison to Industry Standards

• The filing adheres to standard SEC Section 16(a) reporting requirements for executive officers and 10% owners.
• The use of family trusts for estate planning is a common practice among high-net-worth executives in the biotechnology sector.

Related Party Transactions

• The CEO transferred shares to trusts established for his children, which are considered related party transactions under SEC disclosure rules.

Stakeholder Impact

• Minimal impact on shareholders as the total beneficial ownership controlled by the CEO remains largely unchanged.

Next Steps

• None mentioned.

Key Dates

Keywords

Turn Therapeutics, TTRX, Insider Trading, Form 4, Bradley Burnam, Beneficial Ownership